HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs

Civitelli, D. ORCID: 0009-0002-9398-8857, Politopoulou, K., Mills, Mackenzie and Kanavos, P. ORCID: 0000-0001-9518-3089 (2024) HTA18 First to launch, first to falter?: an investigation into the clinical benefits and HTA outcomes for first-in-class drugs. Value in Health, 27 (12, Supplement). S356 - S356. ISSN 1098-3015

Full text not available from this repository.

• https://www.webofscience.com/api/gateway...

Item Type:	Article
Divisions:	LSE Health Health Policy ?? UNIT001541 ?? ?? MTRG ??
Subjects:	R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	20 Mar 2025 15:18
Last Modified:	17 Oct 2025 14:21
URI:	http://eprints.lse.ac.uk/id/eprint/127609

Actions (login required)

View Item